Skip to main content

Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis: A Phase 2 Randomized Clinical Trial

In brief

Brepocitinib cut skin sarcoidosis activity scores by 22 points in phase 2

In a 31-person phase 2 trial, both brepocitinib doses improved skin disease activity by about 22 points at 16 weeks, compared with less than 1 point on placebo. With the higher dose, 69% had clear or almost clear skin versus none on placebo; no serious adverse events occurred. The small trial supports further study, but phase 3 results are still needed.

Journal
JAMA dermatology (Q1)
Published
10 November 2026
Study design
Phase 2 randomized trial (exploratory)
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Misha Rosenbach, Bridget E Shields, Margaret Coates, Ogugua Ndili Obi, Anne L Marano, Aaron R Mangold, et al.
PMID
43008126
DOI
10.1001/jamadermatol.2026.5444

Why clinicians should know about it

  • Picked for Dermatology (paper of the day, 16 November 2026): Randomized trial of targeted therapy for cutaneous sarcoidosis

Abstract

IMPORTANCE: Cutaneous sarcoidosis (CS) is a chronic granulomatous skin disease associated with substantial morbidity and no approved therapies. OBJECTIVE: To evaluate the efficacy and safety of brepocitinib, an oral, selective, tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor, in adults with CS. DESIGN, SETTING, AND PARTICIPANTS: BEACON is an ongoing, global, multicenter, randomized, double-blind, placebo-controlled phase 2/3 trial. This prespecified interim analysis evaluated the 16-week, dose-ranging phase 2 portion of the study conducted between April 9, 2025, and July 18, 2025. Adults with biopsy-proven active CS were randomized 3:2:2 to receive brepocitinib, 45 mg; brepocitinib, 15 mg; or placebo once daily. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was change from baseline in the Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) score at week 16. Additional outcomes included achievement of Cutaneous Sarcoidosis Activity-Investigator Global Assessment (CSA-IGA) clear or almost clear with a 2 or greater category improvement, CSAMI-A response (≥50% relative improvement), 10-point or greater CSAMI-A score reduction, achievement of a CSAMI-A score less than 5, patient-reported outcomes, and safety. RESULTS: Thirty-one participants (mean [SD] age, 53.3 [9.6] years; 18 female individuals [58%] and 13 male individuals [42%]) were enrolled. Both brepocitinib doses achieved rapid, significant improvements in CS disease activity: by week 16, CSAMI-A scores improved by 22.3 points in the 45-mg group and 22.2 points in the 15-mg group compared with a 0.7-point improvement with placebo (P < .001). Across increasingly stringent responder-based and cutaneous remission-oriented end points, efficacy consistently favored brepocitinib, 45 mg, supporting a dose-dependent treatment effect. Compared with placebo, brepocitinib, 45 mg, resulted in higher rates of CSA-IGA clear or almost clear disease (69.2% vs 0%; P = .01), CSAMI-A response (76.9% vs 0%; P = .003), ≥10-point CSAMI-A reduction (100% vs 14.3%; P < .001), and achievement of a CSAMI-A score of less than 5 (61.5% vs 0%; P = .005). Clinical benefit extended to difficult to treat phenotypes, including lupus pernio, despite protocol-mandated systemic glucocorticoid discontinuation, and was accompanied by substantial improvements in skin-related quality of life. No deaths or serious adverse events occurred. CONCLUSIONS AND RELEVANCE: In the phase 2 portion of the BEACON randomized clinical trial, brepocitinib produced rapid, dose-dependent, and clinically meaningful improvements in CS. As the first randomized, placebo-controlled trial to demonstrate efficacy of a targeted therapy in CS, these findings support selective TYK2/JAK1 inhibition as a potentially promising therapeutic strategy for CS and support ongoing phase 3 evaluation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06978725.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.